<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223661</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-IUSCC-0719</org_study_id>
    <nct_id>NCT04223661</nct_id>
  </id_info>
  <brief_title>Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy</brief_title>
  <official_title>Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy in Elderly, Frail Newly Diagnosed Myeloma (MMY2035)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attaya Suvannasankha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if using a subject's baseline frailty score to&#xD;
      guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd&#xD;
      lite).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-institution, prospective, single arm Phase II trial of lenalidomide in a&#xD;
      combination with dexamethasone and daratumumab (DRd lite) with no blinding or randomization.&#xD;
      This study will enroll 44 patients over 36 months.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        1. Evaluate Response rate&#xD;
&#xD;
        2. Evaluate Side effects&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. Evaluate Time on therapy&#xD;
&#xD;
        2. Evaluate Progression free survival&#xD;
&#xD;
        3. Evaluate Time to the next line of therapy&#xD;
&#xD;
        4. Assess Quality of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg, and in frail subjects (frailty score of 2 or higher) will be 5 mg, and escalate to 10 mg.&#xD;
All subjects will receive 20mg Dexamathasone and 1800mg Daratumumab during the course of the trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Based on the International Myeloma Working group criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Based on the International Myeloma Working group criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Based on the International Myeloma Working group criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Best response achieved (up to but no longer than 2 years)</time_frame>
    <description>Based on the International Myeloma Working group criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Side Effects</measure>
    <time_frame>up to 730 days</time_frame>
    <description>Evaluated based on CTCAE version 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time on therapy</measure>
    <time_frame>up to 730 days</time_frame>
    <description>From the start of treatment till the end of treatment (of all 3 drugs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 730 days</time_frame>
    <description>From the start of the treatment until the date of disease progression or death due to any cause. Subjects not progressing or dying will be censored at last disease evaluation date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the next line of therapy</measure>
    <time_frame>up to 730 days</time_frame>
    <description>Duration between the start of the study therapy of all 3 drugs and the start of any new line of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire</measure>
    <time_frame>Monthly (months 1-6), then every 3 months until treatment end (up to but no longer than 2 years)</time_frame>
    <description>EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life- Myeloma</measure>
    <time_frame>Monthly (months 1-6), then every 3 months until treatment end (up to but no longer than 2 years)</time_frame>
    <description>EORTC QLQ-MY20</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Frailty score 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg&#xD;
All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frailty Score 2 or above</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of lenalidomide in frail subjects (frailty score of 2 or higher) will be 5 mg day 1-21 of 28 day cycle, and escalate to 10 mg.&#xD;
All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide Pill</intervention_name>
    <description>Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.</description>
    <arm_group_label>Frailty Score 2 or above</arm_group_label>
    <arm_group_label>Frailty score 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.</description>
    <arm_group_label>Frailty Score 2 or above</arm_group_label>
    <arm_group_label>Frailty score 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose</description>
    <arm_group_label>Frailty Score 2 or above</arm_group_label>
    <arm_group_label>Frailty score 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent and HIPAA authorization for release of personal health&#xD;
             information. NOTE: HIPAA authorization may be included in the informed consent or&#xD;
             obtained separately.&#xD;
&#xD;
          2. Newly diagnosed, symptomatic MM who have frailty score of 1 or higher; patients age ≥&#xD;
             75 or younger patients with comorbidities (&lt;75):&#xD;
&#xD;
             Frailty score takes into account age, as well as the geriatric assessments&#xD;
             incorporating 3 tools: the Katz Activity of Daily Living (ADL), the Lawton&#xD;
             Instrumental Activity of Daily Living (IADL), and the Charlson Comorbidity Index&#xD;
             (CCI)-see detailed tables in Appendix A.&#xD;
&#xD;
             Score calculation tool: www.myelomafrailtyscorecalculator.net&#xD;
&#xD;
          3. ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2 within 14 days&#xD;
             prior to registration.&#xD;
&#xD;
          4. Measurable disease according to the International Myeloma Working Group criteria:&#xD;
&#xD;
               -  Serum M-protein ≥1 g/dL&#xD;
&#xD;
               -  Urine M-protein ≥200 mg/24 h, or&#xD;
&#xD;
               -  Serum FLC (free light-chain) assay: involved FLC level ≥10 mg/dL provided serum&#xD;
                  FLC ratio is abnormal&#xD;
&#xD;
               -  Clonal bone marrow plasma cells ≥ 10%&#xD;
&#xD;
          5. No prior systemic therapy for myeloma is allowed. Surgery such as vertebroplasty or&#xD;
             intramedullary rod placements, and local palliative radiation are allowed as long as&#xD;
             subjects have no residual AEs (adverse events) from prior therapies at the time of&#xD;
             screening&#xD;
&#xD;
          6. Life expectancy of &gt;3 months as determined by the treating physician.&#xD;
&#xD;
          7. Demonstrate adequate organ function as defined in the table below; all screening labs&#xD;
             to be obtained within 14 days prior to registration.&#xD;
&#xD;
             System Laboratory Value Hematological* Absolute Neutrophil Count (ANC) ≥ 1.0 K/mm3&#xD;
             Platelet ≥ 50 K/mm3 Hemoglobin (Hgb) ≥ 8 g/dL Renal Calculated creatinine clearance ≥&#xD;
             30 mL/min using 24 hour urine creatinine clearance Hepatic Bilirubin ≤ 2 × upper limit&#xD;
             of normal (ULN) Aspartate aminotransferase (AST) ≤ 2 × ULN Alanine aminotransferase&#xD;
             (ALT) ≤ 2 × ULN Coagulation International Normalized Ratio (INR) or Prothrombin Time&#xD;
             (PT) Activated Partial Thromboplastin Time (aPTT) ≤ 2 × ULN&#xD;
&#xD;
          8. Females of childbearing potential must have a negative serum pregnancy test within 14&#xD;
             days prior to registration. NOTE: Females are considered of child bearing potential&#xD;
             unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal&#xD;
             ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least&#xD;
             12 consecutive months&#xD;
&#xD;
          9. Females of childbearing potential and males must be willing to abstain from&#xD;
             heterosexual activity or to use one highly effective method of contraception and one&#xD;
             barrier method from the time of informed consent until 3 months after treatment&#xD;
             discontinuation. The birth control method must include one highly effective form of&#xD;
             contraception (tubal ligation, intrauterine device [IUD], hormonal [birth control&#xD;
             pills, injections, hormonal patches, vaginal rings or implants] or partner's vasectomy&#xD;
             with confirmation of procedure) and one additional effective contraceptive method&#xD;
             (male latex or synthetic condom, diaphragm, or cervical cap).&#xD;
&#xD;
         10. As determined by the enrolling physician or protocol designee, ability of the subject&#xD;
             to understand and comply with study procedures for the entire length of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior or concurrent exposure to any of the following:&#xD;
&#xD;
               1. To daratumumab or other anti-CD-38 therapies&#xD;
&#xD;
               2. Maximum of 40 mg dexamethasone (or equivalent) daily for a maximum of 4 days&#xD;
                  consecutively up to 21 days of 1st dose&#xD;
&#xD;
               3. Exposure to investigational drug (including investigational vaccines) or invasive&#xD;
                  investigational medical device for any indication within 4 weeks or 5&#xD;
                  pharmacokinetic half-lives, whichever is longer, before enrollment [Cycle 1, Day&#xD;
                  1 / Randomization]&#xD;
&#xD;
               4. Focal radiation therapy within 14 days prior to enrollmentrandomization with the&#xD;
                  exception of palliative radiotherapy for symptomatic management but not on&#xD;
                  measurable extramedullary plasmacytoma. Radiotherapy within 14 days prior to&#xD;
                  enrollmentrandomization on measurable extramedullary plasmacytoma is not&#xD;
                  permitted even in the setting of palliation for symptomatic management.&#xD;
&#xD;
          2. Known allergies, hypersensitivity, or intolerance to any of the study drugs,&#xD;
             hyaluronidase, mannitol, sorbitol or, corticosteroids, monoclonal antibodies, human&#xD;
             proteins, or their excipients.&#xD;
&#xD;
          3. Active infection requiring systemic therapy&#xD;
&#xD;
          4. Poorly controlled reactive airway diseases including COPD (chronic obstructive&#xD;
             pulmonary disease) or asthma. In subjects with underlying disease of COPD or asthma,&#xD;
             spirometric analysis is recommended. Subjects with FEV1 (forced expiratory volume at&#xD;
             one second) &lt; 50% is excluded.&#xD;
&#xD;
          5. Other medical conditions interfering with the administration of and compliance to&#xD;
             treatments such as Cardiac disease (such as myocardial infarction within past 6&#xD;
             months, uncontrolled cardiac arrhythmia, congestive cardiac failure), major surgeries&#xD;
             within past 2 weeks, plasmapheresis within past 28 days&#xD;
&#xD;
          6. Plasma cell leukemia or amyloidosis&#xD;
&#xD;
          7. Pregnant or breastfeeding&#xD;
&#xD;
          8. Known additional malignancy that is active and/or progressive requiring treatment;&#xD;
             exceptions include basal cell or squamous cell skin cancer, in situ cervical or&#xD;
             bladder cancer, or other cancer for which the subject has been disease-free for at&#xD;
             least five years.&#xD;
&#xD;
          9. Active central nervous system (CNS) involvement by MM&#xD;
&#xD;
         10. Contraindication to receive antiplatelet or anticoagulant prophylaxis&#xD;
&#xD;
         11. Subject is:&#xD;
&#xD;
               1. seropositive for human immunodeficiency virus (HIV)&#xD;
&#xD;
               2. seropositive for hepatitis B (defined by a positive test for hepatitis B surface&#xD;
                  antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg&#xD;
                  negative but positive for antibodies to hepatitis B core antigen [anti-HBc]&#xD;
                  and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened&#xD;
                  using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus&#xD;
                  (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION:&#xD;
                  Subjects with serologic findings suggestive of HBV vaccination (anti-HBs&#xD;
                  positivity as the only serologic marker) AND a known history of prior HBV&#xD;
                  vaccination, do not need to be tested for HBV DNA by PCR.&#xD;
&#xD;
               3. seropositive for hepatitis C (except in the setting of a sustained virologic&#xD;
                  response [SVR], defined as aviremia at least 12 weeks after completion of&#xD;
                  antiviral therapy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Attaya Suvannasankha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Strasburger</last_name>
    <phone>317-988-2162</phone>
    <email>amy.strasburger@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Attaya Suvannasankha, MD</last_name>
    <phone>317-274-0843</phone>
    <email>asuvanna@iu.edu</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Attaya Suvannasankha</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

